Lexicon Pharmaceuticals (LXRX) Return on Capital Employed (2011 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Return on Capital Employed of 11.16% for Q1 2026, up 8356.0% year-over-year from 0.13% in Q1 2025, and up 60.15% quarter-over-quarter from 28.01% in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Return on Capital Employed for 16 consecutive years, with 11.16% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 8356.0% year-over-year to 11.16%; the TTM figure through Mar 2026 stood at 11.16% (up 8356.0% YoY), while the FY2025 annual figure was 22.15%, up 6799.0% from the prior year.
- Return on Capital Employed improved to 11.16% in Q1 2026 per LXRX's latest filing, from 28.01% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 11.16% in Q1 2026 and bottomed at 94.72% in Q1 2025.
- Historically, Return on Capital Employed has averaged 61.18% across 5 years, with a median of 62.0% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed slumped 11610 bps — and 2026, when it jumped 8356 bps.
- Lexicon Pharmaceuticals' Return on Capital Employed stood at 59.33% in 2022, then plunged by 31 bps to 77.57% in 2023, then increased by 4 bps to 74.52% in 2024, then jumped by 62 bps to 28.01% in 2025, then surged by 60 bps to 11.16% in 2026.
- Business Quant data shows LXRX's Return on Capital Employed at 11.16% in Q1 2026, 28.01% in Q4 2025, and 34.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | -22.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.27% |
| Mar 31, 2026 | -11.16% |
| Dec 31, 2025 | -28.01% |
| Sep 30, 2025 | -34.46% |
| Jun 30, 2025 | -52.19% |
| Mar 31, 2025 | -94.72% |
| Dec 31, 2024 | -74.52% |
| Sep 30, 2024 | -67.84% |
| Jun 30, 2024 | -53.63% |
| Mar 31, 2024 | -62.00% |
| Dec 31, 2023 | -77.57% |
| Sep 30, 2023 | -58.75% |
| Jun 30, 2023 | -60.28% |
| Mar 31, 2023 | -68.63% |
| Dec 31, 2022 | -59.33% |
| Sep 30, 2022 | -71.74% |
| Jun 30, 2022 | -89.10% |
| Mar 31, 2022 | -76.19% |
| Dec 31, 2021 | -65.73% |
| Sep 30, 2021 | -50.25% |